Improving Recurrence Prediction Accuracy of Ovarian Cancer Using Multi-phase Feature Selection Methodology

References

• Adorada, A., and A. Wibowo. 2019. Genetic algorithm-based feature selection and optimization of backpropagation neural network parameters for classification of breast cancer using microRNA profiles. 3rd International Conference on Informatics and Computational Sciences (ICICoS), Semarang, Indonesia, 1–6. doi:10.1109/ICICoS48119.2019.8982530.
   Google Scholar
• Bagnoli, M., S. Canevari, D. Califano, S. Losito, M. Di Maio, F. Raspagliesi, M. L. Carcangiu, G. Toffoli, E. Cecchin, R. Sorio, et al. 2016. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: A cohort study. The Lancet Oncology 17 (8):1137–46. doi:10.1016/S1470-2045(16)30108-5.
   PubMed Web of Science ®Google Scholar
• Chakraborty, G., A. Ghosh, S. Nandakumar, J. Armenia, Y. Z. Mazzu, M. O. Atiq, G. M. Lee, L. A. Mucci, T. Merghoub, J. D. Wolchok, et al. 2020. Fraction genome altered (FGA) to regulate both cell autonomous and non-cell autonomous functions in prostate cancer and its effect on prostate cancer aggressiveness. Journal of Clinical Oncology 38 (6_suppl):347–347. doi:10.1200/JCO.2020.38.
   Web of Science ®Google Scholar
• Chakraborty, G., M. Atiq, S. Nandakumar, J. Armenia, Y. Z. Mazzu, G. M. Lee, L. A. Mucci, T. Merghoub, L. A. Mucci ,P.W.Kanto. 2019. A comparative analysis of fraction genome altered vs tumor mutational count in prostate cancer.Molecular and cellular biology/genetics.Proceedings: AACR Annual Meeting 2019, Atlanta, GA. doi:10.1158/1538-7445.
   Google Scholar
• Chen, S. F., Z. Liu, S. Chaurasiya, T. H. Dellinger, J. Lu, X. Wu, H. Qin, J. Wang, Y. Fong, and Y. C. Yuan. 2018. Identification of core aberrantly expressed microRNAs in serous ovarian carcinoma. Oncotarget 9 (29):20451–66. doi:10.18632/oncotarget.24942.
   PubMedGoogle Scholar
• Chu, P., A. Liang, A. Jiang, and L. Zong. 2018. miR-205 regulates the proliferation and invasion of ovarian cancer cells via suppressing PTEN/SMAD4 expression. Oncology Letters 15 (5):7571–78. doi:10.3892/ol.2018.8313.
   PubMed Web of Science ®Google Scholar
• Diaz-Gil, D., F. J. Fintelmann, S. Molaei, A. Elmi, S. S. Hedgire, and M. G. Harisinghani. 2016. Prediction of 5-year survival in advanced-stage ovarian cancer patients based on computed tomography peritoneal carcinomatosis index. Abdominal Radiology (NY) 41 (11):2196–202. doi:10.1007/s00261-016-0817-5.
   PubMed Web of Science ®Google Scholar
• Dong, J., and M. Xu. 2019. A 19 miRNA support vector machine classifier and a 6 miRNA risk score system designed for ovarian cancer patients [published correction appears in Oncol Rep Dec;42(6):2855]. Oncology Reports 41 (6):3233–43. doi:10.3892/or.2019.7108.
   PubMedGoogle Scholar
• Gao, Y. C., X. H. Zhou, and W. Zhang. 2019. An ensemble strategy to predict prognosis in ovarian cancer based on gene modules. Frontiers in Genetics 10:366. doi:10.3389/fgene.2019.00366.
   PubMed Web of Science ®Google Scholar
• Ho, S. Y., J. H. Chen, and M. H. Huang. 2004. Inheritable genetic algorithm for biobjective 0/1 combinatorial optimization problems and its applications. IEEE Transactions on Systems, Man, and Cybernetics. Part B, Cybernetics 34 (1):609–20. doi:10.1109/tsmcb.2003.817090.
   PubMed Web of Science ®Google Scholar
• Hu, K., and M. Liang. 2017. Upregulated microRNA-224 promotes ovarian cancer cell proliferation by targeting KLLN. In Vitro Cellular & Developmental Biology – Animal 53 (2):149–56. doi:10.1007/s11626-016-0093-2.
   PubMed Web of Science ®Google Scholar
• Koutsaki, M., M. Libra, D. A. Spandidos, and A. Zaravinos. 2017. The miR-200 family in ovarian cancer. Oncotarget 8 (39):66629–40. doi:10.18632/oncotarget.18343.
   PubMedGoogle Scholar
• Li, J., X. Han, Y. Wan, S. Zhang, Y. Zhao, R. Fan, Q. Cui, and Y. Zhou. 2018. TAM 2.0: Tool for MicroRNA set analysis. Nucleic Acids Research 46 (W1):W180–W185. doi:10.1093/nar/gky509.
   PubMed Web of Science ®Google Scholar
• Li, Y., and K. V. Kowdley. 2012. MicroRNAs in common human diseases. Genomics, Proteomics & Bioinformatics 10 (5):246–53. doi:10.1016/j.gpb.2012.07.005.
   PubMedGoogle Scholar
• Lu, J., G. Getz, E. A. Miska, E. Alvarez-Saavedra, J. Lamb, D. Peck, A. Sweet-Cordero, B. L. Ebert, R. H. Mak, A. A. Ferrando, et al. 2005. MicroRNA expression profiles classify human cancers. Nature 435 (7043):834–38. doi:10.1038/nature03702.
   PubMed Web of Science ®Google Scholar
• Mehta, K. R., K. Nakao, M. B. Zuraek, D. T. Ruan, E. K. Bergsland, A. P. Venook, D. H. Moore, T. A. Tokuyasu, A. N. Jain, R. S. Warren, et al. 2005. Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer. Clinical Cancer Research 11 (5):1791–97. doi:10.1158/1078-0432.CCR-04-1418.
   PubMed Web of Science ®Google Scholar
• Ohshiro, A., and S. Ueda. 2018. Comparative study of explanatory factor analysis for construction of Clinical Research education model. IJCSNS International Journal of Computer Science and Network Security 18 (3):27–30.
   Web of Science ®Google Scholar
• Paik, E. S., J. W. Lee, J. Y. Park, J. H. Kim, M. Kim, T. J. Kim, C. H. Choi, B. G. Kim, D. S. Bae, and S. W. Seo. 2019. Prediction of survival outcomes in patients with epithelial ovarian cancer using machine learning methods. Journal of Gynecologic Oncology 30 (4):e65. doi:10.3802/jgo.2019.30.e65.
   PubMed Web of Science ®Google Scholar
• Razak, E., F. Yusof, and R. A. Raus. 2019. Cancer relapse prediction from microrna expression data using machine learning. Journal of Mechanics of Continua and Mathematical Sciences (Special Issue–1):365–73. doi:10.26782/jmcms.2019.03.00035.
   Google Scholar
• Sathipathi, Y. S., H. L. Huang, and S. Y. Ho. 2016. Estimating survival time of patients with glioblastoma multiforme and characterization of the identified microRNA signatures. BMC Genomics 17 (Suppl 13):1022. doi:10.1186/s12864-016-3321-y.
   PubMedGoogle Scholar
• Sathipathi, Y. S., and S. Y. Ho. 2018. Identifying a miRNA signature for predicting the stage of breast cancer. Scientific Reports 8. doi:10.1038/s41598-018-34604-3.
   Web of Science ®Google Scholar
• Shimizu, A., K. Sawada, and T. Kimura. 2019. Development of novel approaches to detect ovarian cancer recurrence. Journal of Medical Artificial Intelligence 2:3. doi:10.21037/jmai.2019.02.02.
   Google Scholar
• Siegel, R. L., K. D. Miller, and A. Jemal. 2018. Cancer statistics. CA: A Cancer Journal for Clinicians 68 (1):7–30. doi:10.3322/caac.21442.
   PubMed Web of Science ®Google Scholar
• Sujamol, S., S. Ashok, and U. Krishnakumar. 2018a. Study of fuzzy cognitive maps for modeling clinical support systems. International Journal of Pure and Applied Mathematics 119 (12):15433–45. 1314-3395.
   Google Scholar
• Sujamol, S., S. Ashok, U. Krishnakumar, and C. S. Anoob. 2018b. A genetically optimized method for weight updating in fuzzy cognitive maps. 2018 International Conference on Emerging Trends and Innovations In Engineering And Technological Research (ICETIETR), Ernakulam, 1–5. doi:10.1109/ICETIETR.2018.8529036.
   Google Scholar
• Tian, X., L. Xu, and P. Wang. 2015. MiR-191 inhibits TNF-α induced apoptosis of ovarian endometriosis and endometrioid carcinoma cells by targeting DAPK1. International Journal of Clinical and Experimental Pathology 8 (5):4933–42. Published 2015 May 1.
   PubMed Web of Science ®Google Scholar
• Tsai, M. J., J. R. Wang, C. D. Yang, K. C. Kao, W. L. Huang, H. Y. Huang, C. P. Tseng, H. D. Huang, and S. Y. Ho. 2018. PredCRP: Predicting and analysing the regulatory roles of CRP from its binding sites in Escherichia coli. Scientific Reports 8 (1):951. Published 2018 Jan 17. doi:10.1038/s41598-017-18648-5.
   PubMedGoogle Scholar
• Tung, C. W., and S. Y. Ho. 2007. POPI: Predicting immunogenicity of MHC class I binding peptides by mining informative physicochemical properties. Bioinformatics 23 (8):942–49. doi:10.1093/bioinformatics/btm061.
   PubMed Web of Science ®Google Scholar
• Vistad, I., L. Bjørge, O. Solheim, B. Fiane, K. Sachse, J. Tjugum, S. Skrøppa, A. G. Bentzen, T. Stokstad, G. A. Iversen, et al. 2017. A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway. Acta obstetricia et gynecologica Scandinavica 96 (10):1162–69. doi:10.1111/aogs.13199.
   PubMed Web of Science ®Google Scholar
• Vlachos, I. S., K. Zagganas, M. D. Paraskevopoulou, G. Georgakilas, D. Karagkouni, T. Vergoulis, T. Dalamagas, and A. G. Hatzigeorgiou. 2015. DIANA-miRPath v3.0: Deciphering microRNA function with experimental support. Nucleic Acids Research 43 (W1):W460–W466. doi:10.1093/nar/gkv403.
   PubMed Web of Science ®Google Scholar
• Wang, J. R., W. L. Huang, M. J. Tsai, K. T. Hsu, H. L. Huang, and S. Y. Ho. 2017. ESA-UbiSite: Accurate prediction of human ubiquitination sites by identifying a set of effective negatives. Bioinformatics 33 (5):661–68. doi:10.1093/bioinformatics/btw701.
   PubMed Web of Science ®Google Scholar
• Wang, L., M. J. Zhu, A. M. Ren, H. F. Wu, W. M. Han, R. Y. Tan, and R. Q. Tu. 2014. A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. PLoS One 9 (5):e96472. doi:10.1371/journal.pone.0096472.
   PubMed Web of Science ®Google Scholar
• Yang, K., Y. Hou, A. Li, Z. Li, W. Wang, H. Xie, Z. Rong, G. Lou, and K. Li. 2017. Identification of a six-lncRNA signature associated with recurrence of ovarian cancer. Scientific Reports 7 (1):752. doi:10.1038/s41598-017-00763-y.
   PubMedGoogle Scholar
• Yu, X., X. Zhang, T. Bi, Y. Ding, J. Zhao, C. Wang, T. Jia, D. Han, G. Guo, B. Wang, et al. 2013. MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 34 (6):3501–08. doi:10.1007/s13277-013-0928-3.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., J. Chen, Y. Wang, D. Wang, W. Cong, B. S. Lai, and Y. Zhao. 2019. Multilayer network analysis of miRNA and protein expression profiles in breast cancer patients. PLoS One 14 (4):e0202311. Published 2019 Apr 4. doi:10.1371/journal.pone.0202311.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., Q. Ye, J. He, P. Chen, J. Wan, J. Li, Y. Yang, and X. Li. 2020. Recurrence-associated multi-RNA signature to predict disease-free survival for ovarian cancer patients. BioMed Research International 2020:1618527. doi:10.1155/2020/1618527.
   PubMed Web of Science ®Google Scholar
• Zhao, H., E. Guo, T. Hu, Q. Sun, J. Wu, X. Lin, D. Luo, C. Sun, C. Wang, B. Zhou, et al. 2016. KCNN4 and S100A14 act as predictors of recurrence in optimally debulked patients with serous ovarian cancer. Oncotarget 7. doi:10.18632/oncotarget.9721.
   Google Scholar
• Zhou, J., L. Li, L. Wang, X. Li, H. Xing, and L. Cheng. 2018. Establishment of a SVM classifier to predict recurrence of ovarian cancer. Molecular Medicine Reports 18 (4):3589–98. doi:10.3892/mmr.2018.9362.
   PubMed Web of Science ®Google Scholar